SEC 13F Intelligence

Managers / Q3 2024 · view latest →

Artia Global Partners LP

CIK 0001937964 · 1 SE 3RD AVENUE, STE 2120, MIAMI, FL, 33131 · 3057101384

Reported Value
$367M
Q3 2024
Positions
45
Filings on Record
15
2019–present window
Filed
Nov 14, 2024
original filing

Summary

Artia Global Partners LP reported $367M in U.S.-listed holdings across 45 positions for Q3 2024.

The portfolio is heavily concentrated: NVO alone accounts for 24.1% of reported value.

Compared with Q2 2024, the fund opened 7 new positions and exited 9.

Portfolio Metrics

Turnover
+12.3%
vs prior filed quarter
Top-10 Concentration
+77.4%
share of reported value
Largest Position
+24.1%
Novo Nordisk A S
New / Exited
7 / 9
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $262MQ4 ’22Q1 ’23: $271MQ2 ’23: $290MQ2 ’23Q3 ’23: $241MQ4 ’23: $344MQ4 ’23Q1 ’24: $498MQ2 ’24: $517MQ2 ’24Q3 ’24: $367MQ4 ’24: $280MQ4 ’24Q1 ’25: $395MQ2 ’25: $416MQ2 ’25Q3 ’25: $631MQ4 ’25: $706MQ4 ’25Q1 ’26: $499Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 65.6%ADR: 32.6%Other: 1.8%
  • Common Stock · 65.6% · $241M
  • ADR · 32.6% · $120M
  • Other · 1.8% · $6M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
RVMDREVOLUTION MEDICINES INCNEW+95.9K95.9K+$4M$4M
NUVLNUVALENT INCNEW+15.4K15.4K+$2M$2M
260CENTESSA PHARMACEUTICALS PLCNEW+80.4K80.4K+$1M$1M
ALECALECTOR INCNEW+193.3K193.3K+$900,857$900,857
ACELYRIN INCNEW+93.1K93.1K+$459,052$459,052
SMMTSUMMIT THERAPEUTICS INCNEW+14.5K14.5K+$317,813$317,813
QTTBQ32 BIO INCNEW+4.7K4.7K+$209,937$209,937
SLNOEURSOLENO THERAPEUTICS INCADDED+180.0K274.4K+$10M$14M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2024

44 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1NVONOVO-NORDISK A Shistory →ADR24.07%$88M741.7K
2LLYELI LILLY & COhistory →COM22.36%$82M92.6K
3VKTXVIKING THERAPEUTICS INChistory →COM9.20%$34M532.9K
4ITCIEURINTRA-CELLULAR THERAPIES INChistory →COM4.32%$16M216.5K
5AZNNASTRAZENECA PLChistory →SPONSORED ADR4.05%$15M190.8K
6SLNOEURSOLENO THERAPEUTICS INChistory →COM3.78%$14M274.4K
7ALNYALNYLAM PHARMACEUTICALS INChistory →COM2.62%$10M35.0K
8VRTXVERTEX PHARMACEUTICALS INChistory →COM2.40%$9M18.9K
9PCVXVAXCYTE INChistory →COM2.38%$9M76.3K
10ARGXARGENX SEhistory →SPONSORED ADR2.24%$8M15.1K
11AXSMAXSOME THERAPEUTICS INChistory →COM2.15%$8M87.8K
12PTGXPROTAGONIST THERAPEUTICS INChistory →COM1.53%$6M124.4K
13NBIXNEUROCRINE BIOSCIENCES INChistory →COM1.41%$5M45.0K
14RVMDREVOLUTION MEDICINES INChistory →COM1.19%$4M95.9K
15DYNDYNE THERAPEUTICS INChistory →COM1.17%$4M119.5K
16VRNAVERONA PHARMA PLChistory →SPONSORED ADS1.17%$4M148.6K
17MERUS N VCOM1.09%$4M80.2K
18IM8NINSMED INChistory →COM PAR $.011.05%$4M52.9K
19TCE2CELLDEX THERAPEUTICS INC NEWCOM NEW0.70%$3M75.3K
20CRNXCRINETICS PHARMACEUTICALS INCOM0.64%$2M45.8K
21IDYAIDEAYA BIOSCIENCES INCCOM0.54%$2M63.0K
22MREOMEREO BIOPHARMA GROUP PLCSPON ADS0.47%$2M421.4K
23SWTXUSDSPRINGWORKS THERAPEUTICS INCCOM0.47%$2M53.9K
24NUVLNUVALENT INCCOM0.43%$2M15.4K
25XENEXENON PHARMACEUTICALS INCCOM0.43%$2M40.0K
26260CENTESSA PHARMACEUTICALS PLCSPONSORED ADS0.35%$1M80.4K
27EYPTEYEPOINT PHARMACEUTICALS INCCOM NEW0.34%$1M156.3K
28CHARLES RIV LABS INTL INCCOM0.34%$1M6.3K
29ISIIONIS PHARMACEUTICALS INCCOM0.33%$1M30.5K
30KROSKEROS THERAPEUTICS INCCOM0.32%$1M20.0K
31KURAKURA ONCOLOGY INCCOM0.30%$1M57.2K
32ASCENDIS PHARMA A/SSPONSORED ADR0.30%$1M7.4K
33ANNXANNEXON INCCOM0.28%$1M172.2K
34CRBPCORBUS PHARMACEUTICALS HLDGSCOM NEW0.27%$977,86247.4K
35SLNSILENCE THERAPEUTICS PLCADS0.26%$954,01452.5K
36SNDXSYNDAX PHARMACEUTICALS INCCOM0.25%$929,06348.3K
37NEWAMSTERDAM PHARMA COMPANYORDINARY SHARES0.25%$901,13154.3K
38ALECALECTOR INCCOM0.25%$900,857193.3K
39IRONDISC MEDICINE INCCOM0.18%$660,44213.4K
40LRMRLARIMAR THERAPEUTICS INCCOM0.16%$592,71090.5K
41ACELYRIN INCCOM0.13%$459,05293.1K
42MDGLMADRIGAL PHARMACEUTICALS INCCOM0.09%$330,4271.6K
43SMMTSUMMIT THERAPEUTICS INCCOM0.09%$317,81314.5K
44QTTBQ32 BIO INCCOM0.06%$209,9374.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$499M50May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$706M55Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$631M51Nov 14, 2025RESTATEMENTchanges · EDGAR ↗
Q2 2025$416M37Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$395M38May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$280M37Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$367M45Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$517M46Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$498M49May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$344M31Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$241M27Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$290M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$271M36May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$262M25Feb 14, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.